Classical HLA class I antigen downregulation and abnormal HLA-G expression in ovarian cancer

Min Jong Song1, Suk Il Jang2, Hyon Jee Yoon1, Eun Young Ki3, Joon Mo Lee2, Soo Young Hur2, *

1 Department of Obstetrics and Gynecology, Youido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 07345 Seoul, Korea
2 Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591 Seoul, Korea
3 Department of Obstetrics and Gynecology, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 34943 Daejeon, Korea

*Correspondence: bitsugar74@gmail.com; hursy@catholic.ac.kr (Soo Young Hur)

DOI: 10.31083/j.ejgo.2021.01.5423

Objective: To elucidate the potential role of HLA-G and classical HLA class I molecules in ovarian cancer, we researched their patterns of expression in benign and malignant ovarian tumors. Methods: In 10 benign and 33 malignant ovarian tumor tissues, HLA-G expression was determined both at the mRNA level by reverse transcriptase-polymerase chain reaction and immunohistochemical staining. The expression of classical HLA class I heavy chains were determined immunohistochemically. Results: Immunohistochemical analysis revealed the expression of HLA-G molecules in 27 of the 33 (81.8%) ovarian cancers but in none of the benign ovarian tumors. Classical HLA class I antigen expression was down-regulated in 25 out of the 33 (75.8%) ovarian cancers and in only 1 of the 10 benign ovarian tumors. HLA-G expression and classical HLA class I antigen down-regulation were related to disease stage (Spearman’s ρ = 0.468, P = 0.001; Spearman’s ρ = -0.392, P = 0.005). Conclusion: Our results reveal that abnormal expression of HLA-G and down-regulation of classical HLA class I antigen in ovarian cancer may be one of the mechanisms by which cancer cells may escape host’s immune system.

Keywords
Ovarian cancer; Immune escape; Human leukocyte antigen class I molecule; Human leukocyte antigen-G

1. Introduction
Ovarian cancer is one of the most intractable gynecologic malignancies. Unfortunately, ovarian cancer does not commonly show any signs or symptoms and it is diagnosed as being already progressed in approximately 75% of patients. Despite aggressive treatment, such as cytoreductive surgery followed by adjuvant chemotherapy, the prognosis of advanced ovarian cancer remains poor. The primary reasons why ovarian cancer is difficult to treat ovarian cancer are the imperfect understanding of its etiology and the very few available diagnostic molecular markers and therapeutic targets. To date, various modalities for the early diagnosis and treatment of ovarian cancer have been examined [1–3].

Human leukocyte antigen (HLA) bind-antigenic peptides derived mostly, but not exclusively from endogenous proteins. Following their expression on cell surface, HLA class I antigen complexes interact with T-lymphocyte receptors and thereby activates the immune system. HLA molecules present tumor-specific antigens, non-self antigens from the interior of the cell, as well as antigens from invaders outside the cell. These antigens are recognized by the immunosurveillance system and then removed. Because HLA molecules present tumor-antigens, the phenotypic transformation and debilitation of the immunosurveillance system seems to be mandatory for the development and growth of the tumor [4, 5].

Defects in classical HLA class I molecule expression have been reported in many types of tumor cells [5, 6]. Once classical HLA class I antigen expression has been completely lost, cancer cells are not recognized and lysed by cognate cytotoxic lymphocytes (CTLs). However, this suppression activates natural killer (NK) cells and thereby triggers NK cell-mediated lysis [7]. Therefore, the survival of the tumor cells requires additional mechanisms to prevent NK cell-induced lysis. Recent studies have shown that HLA-G, one of the non-classical HLA class I molecules, protects the cells from the lysis by NK cells. Moreover, it does not mediate the autologous immune responses by T lymphocytes present in peripheral blood [8].

HLA-G was first identified as being expressed in extravillous cytotrophoblast cells, and has been reported to play a key role in providing the fetus, a semi-allograft, with immune tolerance from the maternal immune system [9]. According to recent studies, HLA-G is also expressed in various types of malignant cancers, including breast cancer, colorectal cancer, lung cancer, melanoma, and leukemia [10–14]. In terms of HLA-G expression in ovarian cancer, Malmberg et al. [15] reported that HLA-G expression gradually decreased in cells forming ovarian cancer tissues when cultured for a short-term period. Moreover, Singer et al. [16] reported that 61% of ovarian serous carcinomas demonstrated HLA-G immunoreactivity on the basis of immunohistochemistry. To date, however, no studies have examined the potential clinical relevance of HLA-G expression in combination with classical HLA class I antigens in ovarian cancer. In the present
study, HLA-G and classical HLA class I antigen expression was examined at the transcript levels in benign and malignant ovarian tumors. In addition, an analysis was performed to identify correlations between their expression levels and clinical characteristics to examine whether HLA-G expression could be further used to clarify the immune escape mechanisms utilized by tumor cells in ovarian cancer patients.

2. Materials and methods

2.1 Ovarian cancer tissue

Benign ovarian tumor tissue and malignant ovarian tumor tissue were sampled from 10 and 33 patients, respectively, who underwent surgery to treat ovarian tumors at Seoul St. Mary’s Hospital from March 2012 to December of 2016. The tissue samples were stored in liquid nitrogen (-70 °C) until further use. None of the patients underwent preoperative radiotherapy or anti-cancer chemotherapy. The histological classification of the tumors was based on the World Health Organization (WHO) system [17]; the staging of the disease was based on the International Federation of Gynecologists and Obstetricians (FIGO) staging system [18].

The age distribution of the 10 patients with benign ovarian tumors ranged from 16-76 years. Based on histopathological findings, 1 patient had a Brenner tumor; 5, serous cystadenoma; 1, serous cystadenofibroma; and 3, mucinous cystadenoma. The 33 patients with malignant ovarian tumors had an age distribution ranging from 25 to 73 years. Histopathologically, 20 patients had serous cystadenocarcinoma; 5, mucinous cystadenocarcinoma; 5, endometrioid carcinoma; 1, a mixed germ-cell tumor, 1, a clear-cell carcinoma, and 1, a small-cell carcinoma. Based on the degree of histological differentiation [19], there were 3 well-differentiated cases, 13 moderately differentiated cases, and 17 poorly differentiated cases. Meanwhile, based on the FIGO staging system, 9 cases of Ia, 1 case of Ib, 1 case of Ic, 1 case of IIa, 1 case of IIa, and 20 cases of IIc were observed. In this study, the choriocarcinoma cell line JEG-3 served as the positive control because HLA-G is expressed in this cell line, whereas the human leukemia cell line K562 was used as the negative control because it lacks HLA-G expression.

2.2 Monoclonal antibodies

The monoclonal antibody (mAb), HC-10 [20], which recognizes β2m-free HLA-A3, -A10, -A28, -A29, -A30, -A31, -A32, -A33, and all β2m-free HLA-B (excluding -B5702, -B5804, and -B73) and HLA-C heavy chains was developed and characterized as described [21–23]. mAb was purified from ascitic fluid by affinity chromatography on Protein A. Activity and purity of mAb preparations were monitored by binding assays and SDS-PAGE. mAb MEM-G1 [24] which recognizes denatured HLA-G heavy chain was purchased from Abcam (Cambridge, MA, USA).

2.3 RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)

RNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. First-strand cDNA synthesis was performed using 2 μg of RNA and avian myeloblastosis reverse transcriptase (first-strand synthesis kit for RT-PCR, Mannheim, Germany). For the synthesis of cDNA, annealing was performed at 25 °C for 10 minutes, and an extension was performed at 42 °C for 90 minutes. For inactivating the reverse transcriptase, the sample was maintained at 94 °C for 5 minutes in a Takara MP thermal cycler (Shiga, Japan). The Pan-HLA-G primer set was used for the amplification of HLA-G alternative transcripts, while the β-actin primer set was used to amplify β-actin as an internal standard [25]. Both primer sets were purchased in a customized order from Genotech (Seoul, Korea) for the current experimental procedures. For the amplification of each cDNA, 1 μL of cDNA generated through the RT-PCR was added to a mixture containing 10 μL of 1 × reaction buffer (10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.1% Triton X-100; Boehringer Mannheim), 2.5 μL of 2.5 mM dNTPs, 0.5 μL of sense primer, 0.5 μL of antisense primer, and a 1.25 U of Taq DNA polymerase (Boehringer Mannheim). The reaction volume was brought to a total volume of 25 μL using distilled water. The PCR conditions included denaturation for 1 minute at 94 °C, annealing for 1 minute at 62 °C for β-actin and for 2 minutes at 63 °C for HLA-G, and an extension for 2 minutes at 72 °C, with the respective cycles repeated 25 times for β-actin and 35 times for HLA-G. The PCR products were separated on a 2% agarose gel at 3-4 V/cm, stained using 0.5 μg/mL ethidium bromide, and photographed using a UV transilluminator.

2.4 Immunohistochemical staining

Immunohistochemical staining was done with a CAP- Plus Detection Kit (ZYMED Laboratories Inc., San Francisco, CA, USA) using methods involving Streptavidin-biotin (sABC)/horse radish peroxidase (HRP) complexes. The samples were fixed using 10% neutral buffered formalin, and prepared paraffin-embedded tissue was sequentially sectioned at a thickness of 3 μm. The sections were then placed on ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA, USA) previously coated with poly-L-lysine and dried. The slides were deparaffinized in 2 rinses (5 min each) of a mixture of xylene and Histo-clear II (National diagnostics, Atlanta, GA, USA) and then rinsed twice (5 minutes each) in 100% ethanol. Next, the slides were treated with a TBS solution (ScyTek Lab., Logan, UT, USA) with 3% H2O2 at 45 °C for 10 minutes to remove endogenous peroxidase activity. The samples were rinsed with TBS, placed in 10 mM citrate buffer (pH 6.0; DakoCytomation), and autoclaved for 15 minutes.

For observing HLA-G expression, the slides were incubated with a 1 : 100 dilution of MEM-G1 at 4 °C for 24 hours. The samples were rinsed with TBS and then treated with biotinylated antimouse immunoglobulin antibody (ZYMED Laboratories Inc.) for 30 minutes at 45 °C. After being rinsed
Fig. 1. Reverse transcription–polymerase chain reaction analysis of HLA-G in benign ovarian tumor tissues from patient T1-10. HLA-G alternative transcripts were detected by amplification using pan-HLA-G primers, G-257 and G-1004. As a positive control, JEG-3 cell line were used. Beta-actin gene amplification was used as an internal control.

Table 1. Clinical, histological and immunohistochemical data in 10 benign ovarian tumor patients.

| No | Age | Tumor Histology | Tumor RT-PCR | HLA-G Transcripts | HLA-G Protein | HLA class I |
|----|-----|-----------------|--------------|-------------------|---------------|-------------|
| B1 | 57  | Brenner tumor   | -            | 0                 | 3             |             |
| B2 | 55  | mucinous cystadenoma | -           | 0                 | 4             |             |
| B3 | 36  | mucinous cystadenoma | -           | 0                 | 4             |             |
| B4 | 75  | mucinous cystadenoma | -           | 0                 | 4             |             |
| B5 | 24  | serous cystadenoma | -            | 0                 | 4             |             |
| B6 | 65  | serous cystadenoma | -            | 0                 | 4             |             |
| B7 | 76  | serous cystadenofibroma | -         | 0                 | 4             |             |
| B8 | 24  | serous cystadenoma | -            | 0                 | 4             |             |
| B9 | 16  | serous cystadenoma | -            | 0                 | 4             |             |
| B10| 48  | serous cystadenoma | -            | 0                 | 4             |             |

RT-PCR, reverse transcription–polymerase chain reaction; IHC, immunohistochemistry; *Scoring of immunohistochemical staining was performed as follows: 0, no reactivity; 1, staining confined to ≤ 5% of cell; 2, 6-25% of cell; 3, 26-50% of cell; 4, > 50% of cells were positive.

With TBS, the samples were incubated with streptavidin-HRP complex for 30 minutes. After the samples were rinsed with TBS, the color was developed using an aminoethylcarbazole (AEC) solution and counterstained with hematoxylin. For observing HLA class I expression, the samples were incubated with HC-10 (1 : 100 dilution) at 4°C for 24 hours. The immunohistochemical staining was then performed in the same manner as that for HLA-G expression.

The immunohistochemical staining was recorded as light-microscopy images, and the findings were interpreted by one pathologist. For the exclusion of false-positive results resulting from the staining of areas adjacent to the tissue sample, the interpretation of the staining patterns was performed using the central area of the tissue sample. The staining properties were evaluated based on a 5-grade scoring system as follows: 0 points (< 1%), 1 point (1-5%), 2 points (6-25%), 3 points (26-50%), and 4 points (51-100%).

2.5 Statistical analysis

A correlation analysis of clinical parameters and the expression pattern of HLA class I and HLA-G molecules was performed using Spearman’s rho, with the statistical significance evaluated using SPSS (version 13 for Window, SPSS Inc., Chicago, IL, USA). A value of $P < 0.05$ was considered statistically significant.

2.6 Ethical approval

Written informed consent was obtained from all study subjects, and the study was approved by the Institutional Review Board of our institution on April 1st 2012 (KC12TIS0213).

3. Results

3.1 The expression of HLA-G mRNA and HLA class I molecules in benign ovarian tumors

RT-PCR analysis was performed to examine the expression of HLA-G in benign ovarian tumors through the detection of the alternative transcripts HLA-G1, -G2, -G3 and -G4 at the previously reported sizes of 764 bp, 488 bp, 491 bp, and 215 bp, respectively [25, 26]. No HLA-G mRNA was detected in benign ovarian tumor tissue (Fig. 1), and immunohistochemical staining confirmed this lack of HLA-G mRNA expression. In terms of the expression of HLA class I protein, the Brenner tumor showed a moderate staining intensity and was assigned a score of 3 points, whereas the remaining cases were given a score of 4 points, corresponding to a higher degree of expression (Table 1).

3.2 Expression of HLA-G mRNA and protein and of HLA class I heavy chains in malignant ovarian tumor tissue

As shown by RT-PCR, HLA-G transcript was detected in 78.8% (26/33) of the ovarian cancer tissue samples. Of these
26 samples, 4 showed the expression of both HLA-G1 and HLA-G2/G4. Meanwhile, only HLA-G1 was observed in 20 cases, while only HLA-G2/G4 was detected in 2 cases. By contrast, none of the cases showed the expression of HLA-G3 (Table 2, Fig. 2). Neither the alternative transcripts (i.e., HLA-G1 and HLA-G2/G4) nor their synchronous expression showed any relationship with the histologic classification (tumor histology), tumor grade, or surgical stages. HLA-G protein was expressed at differing levels in 81.8% (27/33) of the malignant ovarian tumor tissue samples, but was not detected in 6 cases (Table 2, Fig. 3). With the exception of 1 tumor showing no HLA-G mRNA transcripts but protein expression, these results were in agreement with those of RT-PCR analysis.

The loss of HLA class I expression in the malignant ovarian tumor tissue samples showed a heterogeneous pattern (Table 2, Fig. 4). Of the 33 tumors tested, 6 (18.2%) had complete loss of expression, where 19 cases (57.6%) showed a loss of > 50%.

Next, the scores for the expression of HLA-G were averaged according to the histologic grade of the tumor and the surgical stage (Fig. 5a,b). The malignant tumors were classified as early (Ia–IIc) and advanced (> IIIa). For both the histologic grade and the surgical stages, the scores for HLA-G expression in the malignant tumors were increased relative to those in the benign tumors. Moreover, among the malignant tumors, the scores were significantly increased in cases in which the degree of histologic differentiation was poor (Spearman’s rho = 0.489, P = 0.001) (Fig. 5c) or the tumor stage was advanced (Spearman’s rho = 0.468, P = 0.001) (Fig. 5d).

The scores for the expression of HLA class I were also averaged according to the histologic grade of the tumor and the surgical stages (Fig. 6a,b). For both the histologic grade and the surgical stages, the scores for the expression of HLA class I molecules were meaningfully decreased in the malignant tumors compared to those in the benign ones. Among the malignant tumors, the scores were significantly decreased in cases in which the degree of histologic differentiation was poor (Spearman’s rho = -0.347, P = 0.015) (Fig. 6c) or the disease stage was more advanced (Spearman’s rho = -0.392, P = 0.005) (Fig. 6d).

Next, we examined whether the decreased expression of HLA class I proteins was correlated with the increased expression of HLA-G in cases in which the degree of tumor differentiation was poor or the surgical stage was advanced.
Table 2. Clinical, histological and immunochemical data in 33 ovarian cancer patients.

| No | Age | Tumor Histology | Tumor grade | Stage | RT-PCR (HLA-G transcripts) | IHC* (HLA-G Protein) | IHC* (HLA class I) |
|----|-----|----------------|-------------|-------|-----------------------------|----------------------|-------------------|
| C1 | 73  | SCC            | PD          | Ib    | +(G1)                       | 1                    | 2                 |
| C2 | 59  | SCC            | PD          | IIIc  | +(G1)                       | 1                    | 3                 |
| C3 | 50  | SCC            | MD          | Ia    | -                           | 0                    | 2                 |
| C4 | 45  | SCC            | PD          | Iic   | +(G2/G4)                    | 4                    | 4                 |
| C5 | 47  | CCC            | MD          | Ia    | -                           | 0                    | 3                 |
| C6 | 53  | SCC            | PD          | IIIc  | +(G1)                       | 3                    | 3                 |
| C7 | 72  | SCC            | MD          | Iic   | +(G1)                       | 1                    | 2                 |
| C8 | 64  | SCC            | MD          | Iic   | -                           | 2                    | 2                 |
| C9 | 53  | SCC            | MD          | Iic   | +(G1)                       | 4                    | 3                 |
| C10| 65  | MCC            | MD          | Iic   | +(G1)                       | 4                    | 4                 |
| C11| 61  | MCC            | WD          | Iic   | +(G1, G2/G4)                | 1                    | 2                 |
| C12| 48  | EC             | MD          | Ia    | +(G1)                       | 3                    | 3                 |
| C13| 44  | SCC            | WD          | Iic   | +(G1)                       | 2                    | 3                 |
| C14| 50  | SCC            | PD          | Ia    | -                           | 0                    | 4                 |
| C15| 56  | SCC            | PD          | Iic   | +(G1)                       | 2                    | 4                 |
| C16| 51  | EC             | MD          | Ia    | +(G1)                       | 1                    | 4                 |
| C17| 54  | SCC            | PD          | Ia    | +(G1)                       | 4                    | 3                 |
| C18| 65  | SCC            | PD          | Iic   | +(G1)                       | 1                    | 3                 |
| C19| 44  | SCC            | PD          | Iic   | +(G1)                       | 2                    | 3                 |
| C20| 45  | MCC            | MD          | Ia    | +(G1, G2/G4)                | 1                    | 4                 |
| C21| 60  | EC             | PD          | Ia    | -                           | 0                    | 0                 |
| C22| 46  | MCC            | MD          | Ic    | +(G1)                       | 2                    | 2                 |
| C23| 66  | SmCC           | PD          | Iic   | -                           | 0                    | 0                 |
| C24| 25  | MGT            | WD          | Ia    | +(G1)                       | 3                    | 0                 |
| C25| 39  | SCC            | PD          | Iic   | +(G1)                       | 1                    | 3                 |
| C26| 45  | MCC            | MD          | Iic   | -                           | 0                    | 4                 |
| C27| 58  | EC             | PD          | Iia   | +(G2/G4)                    | 3                    | 3                 |
| C28| 38  | EC             | PD          | Iic   | +(G1)                       | 2                    | 0                 |
| C29| 59  | SCC            | PD          | Iic   | +(G1)                       | 1                    | 0                 |
| C30| 66  | SCC            | PD          | Iic   | +(G1)                       | 3                    | 1                 |
| C31| 45  | SCC            | MD          | Iic   | +(G1, G2/G4)                | 4                    | 4                 |
| C32| 61  | SCC            | PD          | Iic   | +(G1)                       | 1                    | 1                 |
| C33| 69  | SCC            | MD          | Iic   | +(G1, G2/G4)                | 3                    | 0                 |

RT-PCR, reverse transcription-polymerase chain reaction; IHC, immunohistochemistry; SCC, serous cystadenocarcinoma; MCC, mucinous cystadenocarcinoma; EC, endometroid carcinoma; CCC, clear cell carcinoma, MGT, mixed germ cell tumor. SmCC, small cell carcinoma; WD, well differentiated, MD, moderately differentiated, PD, poorly differentiated; *Scoring of immunohisto-chemical staining was performed as follows: 0, no reactivity; 1, staining confined to 5% of cell; 2, 6-25% of cell; 3, 26-50% of cell; 4, > 50% of cells were positive.

To do this, a direct correlation analysis was performed between the expression of HLA class I and HLA-G molecules. No statistical significance was observed (Spearman’s rho = -0.109, P = 0.255). However, upon exclusion of the cases in which the degree of differentiation was poor, the degree of correlation was increased, but was not statistically significant (Spearman’s rho = -0.330, P = 0.062) (Fig. 7).

4. Discussion

HLA plays an essential role in the human immunosurveillance system, and changes in its expression are essential in the suppression and formation of tumors. The abnormal expression of HLA class I molecules enables the immune escape of tumor cells through the failure to present tumor-specific antigens to CTLs. In various tumors, such as breast cancer, head-and-neck cancers, lung cancer, colorectal cancer, uterine cervical cancer, and melanoma, a loss in the expression of HLA class I molecules has been reported to occur in 39%-88% of patients [6, 27]. In the current study, a decreased expression of HLA class I molecules was almost not observed in the benign ovarian tumors but was completely lost in 18.2% of the malignant cancers. Moreover, HLA class I expression was lost by more than 50% in 57.6% of the malignant cancers. In total, 75.8% of the malignant tumor cases showed abnormal expression of HLA class I molecules. These results are in agreement with those by Vitale et al. [28], who observed a loss of HLA class I expression in 37.3% of patients with primary ovarian tumor. Several authors have examined
whether the expression of HLA class I molecules decreased as the tumors progressed from a benign state to a malignant one, but the results have differed among studies. According to Lee et al. [29], HLA class I expression in metastatic ovarian cancers was decreased relative to that in normal tissue. However, these authors noted that the decreased expression was not statistically significant. By contrast, Vitale et al. [28] reported that the expression of HLA class I molecules was decreased in advanced tumors with a poor degree of differentiation in a high-risk group of patients when compared to that in tumors in a low-risk group of patients. In the current study, depending on the degree of differentiation and the progression of the disease stage, HLA class I expression was significantly decreased. These results indicate that decreased HLA class I expression might play a key role in the infiltrative progression of ovarian tumor cells and may thereby function as one of the possible mechanisms of immune escape [30].

Through the abnormal expression of HLA class I molecules, tumor cells can avoid the immune responses resulting from CTLs. Nevertheless, a complete loss of HLA class I expression would enhance the sensitivity of tumor cells to NK cells, since HLA class I proteins are ligands effectively bound by killer inhibitory receptors on the surface of NK cells [7].

Despite the immune surveillance functions of NK cells, tumor cells show a metastasizing tendency, implying that tumor cells have additional mechanisms for resisting NK-mediated cell cytolysis during the natural course of their growth. That is, the progression and metastasis of tumors occurs through the immune selection of tumor cells that newly express other types of killer inhibitory receptor ligands synchronously with the decreased HLA class I expression.

HLA-G is an effective ligand for various types of NK inhibitory receptors, and has been reported to interfere with cytolysis by NK cells in vitro [8, 21, 31]. For this reason, the presence of HLA-G expression in tumor cells has been of in-
increasing interest to researchers. Indeed, some cell lines derived from blood tumors or solid tumors feature the expression of HLA-G transcripts [13, 22]. Further, in many cases of malignant melanoma, a higher degree of HLA-G mRNA expression has been found [14, 23]. In comparison with the expression of HLA class I genes, however, the degree of HLA-G transcription has been reported to be relatively lower and more variable, and controversy exists in terms of the protein expression. For example, in cases of malignant melanoma, Paul et al. [32] reported the expression of HLA-G protein in a biopsy sample of malignant melanoma. Meanwhile, Real et al. [33] the expression of HLA-G mRNA in malignant melanoma but observed a lack of protein expression. In addition, Pangault et al. [34] has reported a lack of protein expression in other types of solid tumor. These discrepancies might be due to the difference in the methods for examining the expression of HLA-G mRNA and in the sensitivities of the monoclonal antibodies that were used.

HLA-G forms 7 types of alternative transcripts from the primary transcript through alternative splicing. These transcripts have been classified as encoding the membranous forms (HLA-G1, -G2, -G3 and -G4) and the soluble forms (HLA-G5, -G6 and -G7). Of the isoforms encoded by these alternative transcripts, only HLA-G1 and HLA-G5 form a stereoscopic structure consisting of 3 extracellular domains and a b2-microglobulin in an equivalent manner to other typical types of HLA class I molecules and thereby preserving a binding loop for CD8 [35]. These structures bind to the killer inhibitory receptors and thereby suppress the functions of NK cells, CTLs, and dendritic cells. However, little is known about the role of other types of HLA-G alternative transcripts, and the functions of HLA-G in regulating the alternative splicing remain to be elucidated.

For cases of ovarian cancer, Mamberg et al. [15] reported...
that the expression of HLA-G gradually decreased in ovarian cancer cells cultured for a short-term period. In the current study, the expression of HLA-G transcript was mostly observed in malignant ovarian tumor tissues. In particular, the expression of HLA-G2/G4 was seen in 6 cases; however, the expression of HLA-G3 was not observed in any cases. Further studies are warranted to clarify the significance of the difference in the expression of HLA-G alternative transcripts. In addition, the expression of one of the soluble forms, HLA-G5, was not examined in the current study but deserves further studies to understand the overall pattern of expression for the alternative transcripts.

Several potential mechanisms might be responsible for the discrepancy for cases in which HLA-G transcript but not protein is detected. First, some of the antibodies might lack the sensitivity to detect HLA-G protein when expressed at low levels. Second, HLA-G protein may be translated but might be very unstable, so that its expression cannot be detected. Third, there are factors that suppress the translation of HLA-G mRNA. Fourth, mutations could have developed in the coding or non-coding regions of the gene \cite{36,37}. Mutations can develop in HLA-G genes through epigenetic mechanisms, including DNA methylation and histone deacetylation. These changes can alter gene splicing or transcriptional activity and thereby result in reduced gene expression in an in vitro setting. Such epigenetic changes have been reported to cause an impairment in the expression of HLA-G mRNA \cite{38,39}. To date, however, it has not been definitely clarified whether the differences in the mRNA transcription and protein expression of HLA-G originates from these mechanisms. This must be examined through further experimental studies in an effort to draw definitive conclusions.

No significant correlation has been reported between the clinical and histopathological characteristics of most types of
tumors and the expression of HLA-G. However, in the current study, the expression of HLA-G was significantly increased in the progression of the cancer from a benign tumor to a malignant one. In cases in which the tumor was poorly differentiated, the expression of HLA-G was also significantly increased. This correlation with the clinical characteristics was in agreement with the study by Urosevic et al. [40], which found a significant difference in the expression of HLA-G depending on the histologic grade of the tumors in patients with lung cancer. Moreover, correlations between HLA class I and HLA-G expression were examined in cases in which the degree of histologic differentiation was poor and the surgical stage was advanced. The results showed no statistical significance. However, excluding cases in which the degree of histologic differentiation was poor, the statistical significance was shown to increase, indicating an increase in HLA-G expression and the loss of HLA class I molecules plays a key role in the mechanisms by which tumor cells escape immune detection in cases of poor histologic differentiation.

5. Conclusions

Our results provide the basis for a mechanism by which the immune selection of tumor cells occurs in the avoidance of the cytotoxic anti-cancer tumor response in the ovarian cancer tissues. This suggests that HLA-G plays an important role in avoiding the immunosurveillance system of NK cells in patients with ovarian cancer. In cases of ovarian cancer tissue lacking HLA-G protein expression, however, other mechanisms may interfere with the activity of NK cells. Hence, further studies are warranted to examine whether the expression of HLA-G is correlated with that of HLA class II as well as that of HLA class I. Finally, our results may provide a clue for understanding the mechanisms by which immunological abnormalities occur in patients with ovarian cancer.

Author contributions

SYH conceived and designed the experiments; SIJ, HJY and EYK performed the experiments; SYH and MJS analyzed the data; SIJ and JML contributed reagents and materials; MJS wrote the paper.

Ethics approval and consent to participate

Written informed consent was obtained from all study subjects, and the study was approved by the Institutional Review Board of our institution on April 1st 2012 (KC12TISI0213).

Acknowledgment

We would like to express our gratitude to all those who helped us during the writing of this manuscript and we also appreciate all the peer reviewers and editors for their opinions and suggestions.

Funding

This study was not supported any funding sources.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

[1] Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: A Cancer Journal for Clinicians. 2011; 61: 183-203.
[2] Ministry of Health & Welfare. Annual Report of the Korean Central Cancer Registry, Seoul. 2017.
[3] Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. The Journal of Reproductive Medicine. 2005; 50: 426-438.
[4] Ruiz-Cabello F, Klein E, Garrido F. MHC antigens on human tumors. Immunology Letters. 1991; 29: 181-189.
[5] Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wallich B, et al. Association of HLA class I antigen abnormalities with dis-
ease progression and early recurrence in prostate cancer. Cancer Immunology, Immunotherapy. 2010; 59: 529-540.

[6] Meissner M, Reichert TE, Kunek M, Gooding W, Whiteside TL, Ferrone S, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clinical Cancer Research. 2005; 11: 2552-2560.

[7] Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Seminars in Cancer Biology. 2006; 16: 383-392.

[8] Yan WH. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocrine Metabolic & Immune Disorders-Drug Targets. 2011; 11: 76-89.

[9] Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V. The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cellular and Molecular Life Sciences. 2011; 68: 341-352.

[10] Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, et al. Clinical relevance and functional implications for human leukocyte antigen-G expression in non-small-cell lung cancer. Journal of Cellular and Molecular Medicine. 2010; 14: 2318-2329.

[11] Ye SR, Yang H, Li K, Dong DD, Lin XM, Yue SM. Human leukocyte antigen G expression, as a significant prognostic indicator for patients with colorectal cancer. Modern Pathology. 2007; 20: 375-383.

[12] Chen HX, Lin A, Shen CJ, Zhen R, Chen BG, Zhang X, et al. Up-regulation of human leukocyte antigen-G expression and its clinical significance in duvalt breast cancer. Human Immunology. 2010; 79: 892-898.

[13] Yan WH. HLA-G expression in hematologic malignancies. Expert Review of Hematology. 2010; 3: 67-80.

[14] Yan WH, Lin AF, Chang CC, Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′-deoxycytidine. Cell Research. 2005; 15: 523-531.

[15] Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Fournel S, Huc X, Aguerre-Girr M, Solier C, Legros M, Praud C, Chen HX, Lin A, Shen CJ, Zhen R, Chen BG, et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I antigens and protein expression. Human Immunology. 2000; 61: 1177-1195.

[16] Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Research. 2001; 61: 6838-6845.

[17] Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunology Today. 1997; 18: 89-95.

[18] Vitale M, Pelusi G, Tonioni B, Gobbi G, Micheloni C, Rezzani R, et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clinical Cancer Research. 2005; 11: 67-72.

[19] Lee YS, Kim TE, Kim BK, Park YG, Kim GM, Jee SB, et al. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Experimental & Molecular Medicine. 2002; 34: 18-26.

[20] Shehata M, Mukherjee A, Deen S, Al-Attar A, Durrant LG, Chan S. Human leukocyte antigen class I expression and clinical implications in transplanted patients. European Journal of Immunology. 2004; 34: 649-660.

[21] Schepers N, Busschots M, de Smet I, et al. Differential in vivo expression of HLA-G in melanoma biopsies. Cancer Research. 2003; 59: 1954-1960.

[22] Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, et al. Expression of HLA G in human tumors is not a frequent event. International Journal of Cancer. 1999; 81: 512-518.

[23] Pauwels S, Vandenbulcke J, et al. HLA-G expression in melanoma cells: potential mechanisms. Human Immunology. 2003; 64: 1057-1063.

[24] El-Osta A, Wolffe AP. DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expression. 2000; 9: 63-75.

[25] Moreau P, Mouillot G, Roux JF, et al. HLA-G gene expression is reversed by demethylation. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 1191-1196.

[26] Urosevic M, Kurrer MO, Kamrashve J, Mueller B, Weder W, Burg G, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. American Journal of Pathology. 2001; 159: 817-824.